Unmet needs in paediatric psychopharmacology: Present scenario and future perspectives

Antonio M. Persico, Celso Arango, Jan K. Buitelaar, Christoph U. Correll, Jeffrey C. Glennon, Pieter J. Hoekstra, Carmen Moreno, Benedetto Vitiello, Jacob Vorstman, Alessandro Zuddas, Celso Arango, Tobias Banaschewski, Jan K. Buitelaar, Josefina Castro-Fornieles, David Coghill, David Cohen, Ralf W. Dittmann, Jörg M. Fegert, Pieter J. Hoekstra, Carmen MorenoAntonio M. Persico, Diane Purper Ouakil, Mara Parellada, Veit Roessner, Alessandro Zuddas

Research output: Contribution to journalArticle

Abstract

Paediatric psychopharmacology holds great promise in two equally important areas of enormous biomedical and social impact, namely the treatment of behavioural abnormalities in children and adolescents, and the prevention of psychiatric disorders with adolescent- or adult-onset. Yet, in striking contrast, pharmacological treatment options presently available in child and adolescent psychiatry are dramatically limited. The most important currently unmet needs in paediatric psychopharmacology are: the frequent off-label prescription of medications to children and adolescents based exclusively on data from randomized controlled studies involving adult patients; the frequent lack of age-specific dose, long-term efficacy and tolerability/safety data; the lack of effective medications for many paediatric psychiatric disorders, most critically autism spectrum disorder; the scarcity and limitations of randomized placebo-controlled trials in paediatric psychopharmacology; the unexplored potential for the prevention of psychiatric disorders with adolescent- and adult-onset; the current lack of biomarkers to predict treatment response and severe adverse effects; the need for better preclinical data to foster the successful development of novel drug therapies; and the effective dissemination of evidence-based treatments to the general public, to better inform patients and families of the benefits and risks of pharmacological interventions during development. Priorities and strategies are proposed to overcome some of these limitations, including the European Child and Adolescent Clinical Psychopharmacology Network, as an overarching Pan-European infrastructure aimed at reliably carrying out much needed psychopharmacological trials in children and adolescents, in order to fill the identified gaps and improve overall outcomes.

Original languageEnglish (US)
Pages (from-to)1513-1531
Number of pages19
JournalEuropean Neuropsychopharmacology
Volume25
Issue number10
DOIs
StatePublished - Oct 1 2015
Externally publishedYes

Fingerprint

Psychopharmacology
Pediatrics
Adolescent Psychiatry
Psychiatry
Pharmacology
Child Psychiatry
Therapeutics
Social Change
Prescriptions
Randomized Controlled Trials
Biomarkers
Placebos
Safety
Drug Therapy

Keywords

  • Autism spectrum disorder
  • Biomarkers
  • Intellectual disability
  • Off-label use
  • Pharmaceutical policies
  • Psychopharmacology

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Pharmacology (medical)
  • Biological Psychiatry
  • Neurology
  • Pharmacology

Cite this

Persico, A. M., Arango, C., Buitelaar, J. K., Correll, C. U., Glennon, J. C., Hoekstra, P. J., ... Zuddas, A. (2015). Unmet needs in paediatric psychopharmacology: Present scenario and future perspectives. European Neuropsychopharmacology, 25(10), 1513-1531. https://doi.org/10.1016/j.euroneuro.2015.06.009

Unmet needs in paediatric psychopharmacology : Present scenario and future perspectives. / Persico, Antonio M.; Arango, Celso; Buitelaar, Jan K.; Correll, Christoph U.; Glennon, Jeffrey C.; Hoekstra, Pieter J.; Moreno, Carmen; Vitiello, Benedetto; Vorstman, Jacob; Zuddas, Alessandro; Arango, Celso; Banaschewski, Tobias; Buitelaar, Jan K.; Castro-Fornieles, Josefina; Coghill, David; Cohen, David; Dittmann, Ralf W.; Fegert, Jörg M.; Hoekstra, Pieter J.; Moreno, Carmen; Persico, Antonio M.; Purper Ouakil, Diane; Parellada, Mara; Roessner, Veit; Zuddas, Alessandro.

In: European Neuropsychopharmacology, Vol. 25, No. 10, 01.10.2015, p. 1513-1531.

Research output: Contribution to journalArticle

Persico, AM, Arango, C, Buitelaar, JK, Correll, CU, Glennon, JC, Hoekstra, PJ, Moreno, C, Vitiello, B, Vorstman, J, Zuddas, A, Arango, C, Banaschewski, T, Buitelaar, JK, Castro-Fornieles, J, Coghill, D, Cohen, D, Dittmann, RW, Fegert, JM, Hoekstra, PJ, Moreno, C, Persico, AM, Purper Ouakil, D, Parellada, M, Roessner, V & Zuddas, A 2015, 'Unmet needs in paediatric psychopharmacology: Present scenario and future perspectives', European Neuropsychopharmacology, vol. 25, no. 10, pp. 1513-1531. https://doi.org/10.1016/j.euroneuro.2015.06.009
Persico AM, Arango C, Buitelaar JK, Correll CU, Glennon JC, Hoekstra PJ et al. Unmet needs in paediatric psychopharmacology: Present scenario and future perspectives. European Neuropsychopharmacology. 2015 Oct 1;25(10):1513-1531. https://doi.org/10.1016/j.euroneuro.2015.06.009
Persico, Antonio M. ; Arango, Celso ; Buitelaar, Jan K. ; Correll, Christoph U. ; Glennon, Jeffrey C. ; Hoekstra, Pieter J. ; Moreno, Carmen ; Vitiello, Benedetto ; Vorstman, Jacob ; Zuddas, Alessandro ; Arango, Celso ; Banaschewski, Tobias ; Buitelaar, Jan K. ; Castro-Fornieles, Josefina ; Coghill, David ; Cohen, David ; Dittmann, Ralf W. ; Fegert, Jörg M. ; Hoekstra, Pieter J. ; Moreno, Carmen ; Persico, Antonio M. ; Purper Ouakil, Diane ; Parellada, Mara ; Roessner, Veit ; Zuddas, Alessandro. / Unmet needs in paediatric psychopharmacology : Present scenario and future perspectives. In: European Neuropsychopharmacology. 2015 ; Vol. 25, No. 10. pp. 1513-1531.
@article{00a65c0cb5c74a92b7001b31d4737787,
title = "Unmet needs in paediatric psychopharmacology: Present scenario and future perspectives",
abstract = "Paediatric psychopharmacology holds great promise in two equally important areas of enormous biomedical and social impact, namely the treatment of behavioural abnormalities in children and adolescents, and the prevention of psychiatric disorders with adolescent- or adult-onset. Yet, in striking contrast, pharmacological treatment options presently available in child and adolescent psychiatry are dramatically limited. The most important currently unmet needs in paediatric psychopharmacology are: the frequent off-label prescription of medications to children and adolescents based exclusively on data from randomized controlled studies involving adult patients; the frequent lack of age-specific dose, long-term efficacy and tolerability/safety data; the lack of effective medications for many paediatric psychiatric disorders, most critically autism spectrum disorder; the scarcity and limitations of randomized placebo-controlled trials in paediatric psychopharmacology; the unexplored potential for the prevention of psychiatric disorders with adolescent- and adult-onset; the current lack of biomarkers to predict treatment response and severe adverse effects; the need for better preclinical data to foster the successful development of novel drug therapies; and the effective dissemination of evidence-based treatments to the general public, to better inform patients and families of the benefits and risks of pharmacological interventions during development. Priorities and strategies are proposed to overcome some of these limitations, including the European Child and Adolescent Clinical Psychopharmacology Network, as an overarching Pan-European infrastructure aimed at reliably carrying out much needed psychopharmacological trials in children and adolescents, in order to fill the identified gaps and improve overall outcomes.",
keywords = "Autism spectrum disorder, Biomarkers, Intellectual disability, Off-label use, Pharmaceutical policies, Psychopharmacology",
author = "Persico, {Antonio M.} and Celso Arango and Buitelaar, {Jan K.} and Correll, {Christoph U.} and Glennon, {Jeffrey C.} and Hoekstra, {Pieter J.} and Carmen Moreno and Benedetto Vitiello and Jacob Vorstman and Alessandro Zuddas and Celso Arango and Tobias Banaschewski and Buitelaar, {Jan K.} and Josefina Castro-Fornieles and David Coghill and David Cohen and Dittmann, {Ralf W.} and Fegert, {J{\"o}rg M.} and Hoekstra, {Pieter J.} and Carmen Moreno and Persico, {Antonio M.} and {Purper Ouakil}, Diane and Mara Parellada and Veit Roessner and Alessandro Zuddas",
year = "2015",
month = "10",
day = "1",
doi = "10.1016/j.euroneuro.2015.06.009",
language = "English (US)",
volume = "25",
pages = "1513--1531",
journal = "European Neuropsychopharmacology",
issn = "0924-977X",
publisher = "Elsevier",
number = "10",

}

TY - JOUR

T1 - Unmet needs in paediatric psychopharmacology

T2 - Present scenario and future perspectives

AU - Persico, Antonio M.

AU - Arango, Celso

AU - Buitelaar, Jan K.

AU - Correll, Christoph U.

AU - Glennon, Jeffrey C.

AU - Hoekstra, Pieter J.

AU - Moreno, Carmen

AU - Vitiello, Benedetto

AU - Vorstman, Jacob

AU - Zuddas, Alessandro

AU - Arango, Celso

AU - Banaschewski, Tobias

AU - Buitelaar, Jan K.

AU - Castro-Fornieles, Josefina

AU - Coghill, David

AU - Cohen, David

AU - Dittmann, Ralf W.

AU - Fegert, Jörg M.

AU - Hoekstra, Pieter J.

AU - Moreno, Carmen

AU - Persico, Antonio M.

AU - Purper Ouakil, Diane

AU - Parellada, Mara

AU - Roessner, Veit

AU - Zuddas, Alessandro

PY - 2015/10/1

Y1 - 2015/10/1

N2 - Paediatric psychopharmacology holds great promise in two equally important areas of enormous biomedical and social impact, namely the treatment of behavioural abnormalities in children and adolescents, and the prevention of psychiatric disorders with adolescent- or adult-onset. Yet, in striking contrast, pharmacological treatment options presently available in child and adolescent psychiatry are dramatically limited. The most important currently unmet needs in paediatric psychopharmacology are: the frequent off-label prescription of medications to children and adolescents based exclusively on data from randomized controlled studies involving adult patients; the frequent lack of age-specific dose, long-term efficacy and tolerability/safety data; the lack of effective medications for many paediatric psychiatric disorders, most critically autism spectrum disorder; the scarcity and limitations of randomized placebo-controlled trials in paediatric psychopharmacology; the unexplored potential for the prevention of psychiatric disorders with adolescent- and adult-onset; the current lack of biomarkers to predict treatment response and severe adverse effects; the need for better preclinical data to foster the successful development of novel drug therapies; and the effective dissemination of evidence-based treatments to the general public, to better inform patients and families of the benefits and risks of pharmacological interventions during development. Priorities and strategies are proposed to overcome some of these limitations, including the European Child and Adolescent Clinical Psychopharmacology Network, as an overarching Pan-European infrastructure aimed at reliably carrying out much needed psychopharmacological trials in children and adolescents, in order to fill the identified gaps and improve overall outcomes.

AB - Paediatric psychopharmacology holds great promise in two equally important areas of enormous biomedical and social impact, namely the treatment of behavioural abnormalities in children and adolescents, and the prevention of psychiatric disorders with adolescent- or adult-onset. Yet, in striking contrast, pharmacological treatment options presently available in child and adolescent psychiatry are dramatically limited. The most important currently unmet needs in paediatric psychopharmacology are: the frequent off-label prescription of medications to children and adolescents based exclusively on data from randomized controlled studies involving adult patients; the frequent lack of age-specific dose, long-term efficacy and tolerability/safety data; the lack of effective medications for many paediatric psychiatric disorders, most critically autism spectrum disorder; the scarcity and limitations of randomized placebo-controlled trials in paediatric psychopharmacology; the unexplored potential for the prevention of psychiatric disorders with adolescent- and adult-onset; the current lack of biomarkers to predict treatment response and severe adverse effects; the need for better preclinical data to foster the successful development of novel drug therapies; and the effective dissemination of evidence-based treatments to the general public, to better inform patients and families of the benefits and risks of pharmacological interventions during development. Priorities and strategies are proposed to overcome some of these limitations, including the European Child and Adolescent Clinical Psychopharmacology Network, as an overarching Pan-European infrastructure aimed at reliably carrying out much needed psychopharmacological trials in children and adolescents, in order to fill the identified gaps and improve overall outcomes.

KW - Autism spectrum disorder

KW - Biomarkers

KW - Intellectual disability

KW - Off-label use

KW - Pharmaceutical policies

KW - Psychopharmacology

UR - http://www.scopus.com/inward/record.url?scp=84943348943&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84943348943&partnerID=8YFLogxK

U2 - 10.1016/j.euroneuro.2015.06.009

DO - 10.1016/j.euroneuro.2015.06.009

M3 - Article

C2 - 26166453

AN - SCOPUS:84943348943

VL - 25

SP - 1513

EP - 1531

JO - European Neuropsychopharmacology

JF - European Neuropsychopharmacology

SN - 0924-977X

IS - 10

ER -